| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income, net | 3,391 | 786 | 502 | 1,714 |
| Net loss before income taxes | - | -52,591 | -51,890 | -52,518 |
| Provision for income taxes | - | 0 | - | - |
| Net loss attributable to common stockholders, basic | -50,582 | -52,591 | -51,890 | -52,518 |
| Net loss attributable to common stockholders, diluted | -50,582 | -52,591 | -51,890 | -52,518 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.32 | -0.41 | -0.4 | -0.44 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.32 | -0.41 | -0.4 | -0.44 |
| Weighted-average common shares outstanding, basic (in shares) | 160,503,183 | 129,185,918 | 130,884,490 | 119,764,270 |
| Weighted-average common shares outstanding, diluted (in shares) | 160,503,183 | 129,185,918 | 130,884,490 | 119,764,270 |
Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME)